Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724922 | 0.91 | GLS (0.50) | GLSTSHRALDH1A1SMN1; SMN2DGAT1 | |
| SCHEMBL21443355 | 0.83 | GLS (0.45) | GLSTSHRALDH1A1SMN1; SMN2DGAT1 | |
| SCHEMBL21443408 | 0.77 | GLS (0.67) | GLS | |
| SCHEMBL15724903 | 0.67 | CA1 (0.58) | GLSTSHRALDH1A1HSD17B10POLB | |
| SCHEMBL15725047 | 0.65 | ALDH1A1 (0.63) | GLSTSHRALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL15725232 | 0.65 | ALDH1A1 (0.63) | GLSTSHRALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL15724912 | 0.64 | TSHR (0.51) | GLSTSHRALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL17655079 | 0.64 | GLS (0.71) | GLSALDH1A1HSD17B10CA2 | |
| SCHEMBL14987001 | 0.64 | GLS (0.89) | GLSALDH1A1SMN1; SMN2HSD17B10RAB9A | |
| SCHEMBL15727744 | 0.64 | GLS (0.89) | GLSALDH1A1SMN1; SMN2HSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414740-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414740-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | GLS 1/4885TSHR 4186/4885ALDH1A1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.